Corvus Pharma (CRVS)
11.95
+0.05 (0.42%)
Upcoming Events
Latest Headlines
Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Moore David Scott
June 15, 2026 5:12 PM - SEC Filing
Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: CLARK IAN T
June 15, 2026 5:10 PM - SEC Filing
Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Grais Linda
June 15, 2026 5:08 PM - SEC Filing
Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Thompson Peter A.
June 15, 2026 5:07 PM - SEC Filing
Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: van den Broek Richard
June 15, 2026 5:04 PM - SEC Filing
Form 8-K Corvus Pharmaceuticals, For: Jun 11
June 12, 2026 4:01 PM - SEC Filing
Corvus Pharmaceuticals invests $5 million in Angel Pharmaceuticals
June 9, 2026 7:30 AM - StreetInsider
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China
June 9, 2026 7:30 AM - Globe NewsWire
Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD
May 20, 2026 4:12 PM - SEC Filing
Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026 4:01 PM - Globe NewsWire
Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:20 PM - SEC Filing
Form SCHEDULE 13G Corvus Pharmaceuticals, Filed by: Sirenia Capital Management LP
May 15, 2026 8:11 AM - SEC Filing
Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald
May 15, 2026 7:33 AM - StreetInsider
Form 8-K Corvus Pharmaceuticals, For: May 14
May 14, 2026 7:01 AM - SEC Filing
Corvus Pharmaceuticals presents soquelitinib atopic dermatitis data
May 14, 2026 7:00 AM - StreetInsider
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting
May 14, 2026 7:00 AM - Globe NewsWire
Form S-8 Corvus Pharmaceuticals,
May 7, 2026 5:03 PM - SEC Filing
Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q1 EPS
May 7, 2026 4:24 PM - StreetInsider
Form 10-Q Corvus Pharmaceuticals, For: Mar 31
May 7, 2026 4:06 PM - SEC Filing
Form 8-K Corvus Pharmaceuticals, For: May 07
May 7, 2026 4:02 PM - SEC Filing
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
May 7, 2026 4:01 PM - Globe NewsWire
Form 3 Corvus Pharmaceuticals, For: Apr 23 Filed by: Chan Andrew C.
April 27, 2026 5:33 PM - SEC Filing
Form 4 Corvus Pharmaceuticals, For: Apr 23 Filed by: Chan Andrew C.
April 27, 2026 5:33 PM - SEC Filing
Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: BlackRock, Inc.
April 27, 2026 4:15 PM - SEC Filing
Form DEFA14A Corvus Pharmaceuticals,
April 24, 2026 4:18 PM - SEC Filing
Form DEF 14A Corvus Pharmaceuticals, For: Jun 11
April 24, 2026 4:16 PM - SEC Filing
Form 8-K Corvus Pharmaceuticals, For: Apr 22
April 23, 2026 7:02 PM - SEC Filing
Corvus Pharmaceuticals adds former Genentech executive to board
April 23, 2026 7:30 AM - StreetInsider
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors
April 23, 2026 7:30 AM - Globe NewsWire
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting
April 21, 2026 7:30 AM - Globe NewsWire
Goldman Sachs sees nearly 140% upside in this biopharma stock
April 20, 2026 7:30 AM - StreetInsider
Goldman Sachs Starts Corvus Pharmaceuticals (CRVS) at Buy
April 17, 2026 4:34 AM - StreetInsider
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: VANGUARD GROUP INC
March 26, 2026 5:39 PM - SEC Filing
Full Article List
